In the current study, both Dab2 and E-cadherin mRNA levels were significantly decreased as early as Stage I pancreatic tumors (Fig. 5), suggesting that loss of Dab2 early in pancreatic progression may lead to decreased E-cadherin expression, thereby contributing to the early dissemination of pancreatic cancer. Here, DAB2 is linked to familial pancreatic carcinoma.